Author

Yumi Kubo

Observed name: Kubo, Yumi

Observed institutions: Memorial University of Newfoundland, Amgen (United States), Inserm, Richard L. Roudebush VA Medical Center, Stanford Medicine, Indiana University School of Medicine, University of Glasgow, Stanford University

ORCID: 0000-0002-9506-2612

Observed ORCID: 0000-0002-9506-2612

OpenAlex ID: A5087900277

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis

2015 · Sharon M. Moe, Glenn M. Chertow, et al. · Circulation · 305

PDF

Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial

2014 · David C. Wheeler, Gerard M. London, et al. · Journal of the American Heart Association · 137

PDF

The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis

2015 · Jürgen Floege, Yumi Kubo, et al. · Clinical Journal of the American Society of Nephrology · 134

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Participants With CKD Not Receiving Dialysis

2008 · Michel Chonchol, Francesco Locatelli, et al. · American Journal of Kidney Diseases · 125

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis

2015 · Patrick S. Parfrey, Tilman B. Drüeke, et al. · Clinical Journal of the American Society of Nephrology · 95

PDF

Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers

2018 · Jan de Hoon, Anne Van Hecken, et al. · Cephalalgia · 45

PDF

Analyzing Health-Related Quality of Life in the EVOLVE Trial

2016 · Andrew H. Briggs, Patrick S. Parfrey, et al. · Medical Decision Making · 38

Assessing the treatment effect in a randomized controlled trial with extensive non‐adherence: the EVOLVE trial

2015 · Yumi Kubo, Lulu Ren Sterling, et al. · Pharmaceutical Statistics · 22

Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all‐cause mortality

2015 · Iain A. Gillespie, Jürgen Floege, et al. · Pharmacoepidemiology and Drug Safety · 17

PDF

Relationship between Reductions in Parathyroid Hormone and Serum Phosphorus during the Management of Secondary Hyperparathyroidism with Calcimimetics in Hemodialysis Patients

2012 · Kerry Cooper, Darryl Quarles, et al. · Nephron Clinical Practice · 16

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial

2015 · Patrick S. Parfrey, Tilman B. Drüeke, et al. · RWTH Publications (RWTH Aachen) · 6

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients with Stable Angina (S32.004)

2018 · Christophe Depre, Lubomir Antalik, et al. · Neurology · 3

Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial

2015 · Yumi Kubo, Lulu Ren Sterling, et al. · Pharmaceutical Statistics · 3

PDF

Phase 1, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Erenumab (AMG 334) and Concomitant Sumatriptan on Blood Pressure in Healthy Subjects (P2.161)

2017 · Jan de Hoon, Anne Van Hecken, et al. · Neurology · 2

Contents Vol. 121,2012

2013 · Fuad N. Ziyadeh, Khaled M. Musallam, et al. · The Nephron journals/Nephron journals

Erratum

2013 · Fuad N. Ziyadeh, Khaled M. Musallam, et al. · Nephron Clinical Practice

Front & Back Matter

2012 · Fuad N. Ziyadeh, Khaled M. Musallam, et al. · Nephron Clinical Practice

Works count: 22

Citation count: 973

H-index: 11

I10-index: 11